

Identification of key genes and long non-coding RNAs in celecoxib-treated lung squamous cell carcinoma cell line by RNA-sequencing

GANG LI, XUEHAI WANG, QINGSONG LUO and CHONGZHI GAN

Department of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China

Received November 24, 2016; Accepted August 3, 2017

DOI: 10.3892/mmr.2018.8656

Abstract. Celecoxib is an inhibitor of cyclooxygenase-2, a gene that is often aberrantly expressed in the lung squamous cell carcinoma (LSQCC). The present study aims to provide novel insight into chemoprevention by celecoxib treatment. The human LSQCC cell line SK-MES-1 was treated with or without celecoxib and RNA-sequencing (RNA-seq) was performed on the Illumina HiSeq 2000 platform. Expression levels of genes or long non-coding RNAs (lncRNAs) were calculated by Cufflinks software. Subsequently, differentially expressed genes (DEGs) and differentially expressed lncRNAs (DE-LNRs) between the two groups were selected using the limma package and LNCipedia 3.0, respectively; followed by co-expression analysis based on their expression correlation coefficient (CC). Enrichment analysis for the DEGs and co-expressed DE-LNRs were performed. Protein-protein interaction (PPI) network analysis for DEGs was performed using STRING database. A set of 317 DEGs

and 25 DE-LNRs were identified between celecoxib-treated and non-treated cell lines. A total of 12 pathways were enriched by the DEGs, including 'protein processing in endoplasmic reticulum' for activating transcription factor 4 (*ATF4*), 'mammalian target of rapamycin (mTOR) signaling pathway' for vascular endothelial growth factor A (*VEGFA*) and 'ECM-receptor interaction' for fibronectin 1 (*FNI*). Genes such as *VEGFA*, *ATF4* and *FNI* were highlighted in the PPI network. *VEGFA* was linked with lnc-AP000769.1-2:10 (CC=-0.99227), whereas *ATF4* and *FNI* were closely correlated with lnc-HFE2-2:1 (CC=0.996159 and -0.98714, respectively). lncRNAs were also enriched in pathways such as 'mTOR signaling pathway' for lnc-HFE2-2:1. Several important molecules were identified in celecoxib-treated LSQCC cell lines, such as *VEGFA*, *ATF4*, *FNI*, lnc-AP000769.1-2:10 and lnc-HFE2-2:1, which may enhance the anti-cancer effects of celecoxib on LSQCC.

Introduction

Lung cancer is one of the most frequently diagnosed cancers with high mortality worldwide, with >1,500,000 new cases diagnosed annually (1,2). Based on the cancer statistics data from 2015, lung and bronchial cancers are expected to have the highest mortality among all cancers in the USA, with the estimated mortality rate of 158,040 (3). Lung squamous cell carcinoma (LSQCC) is the second most common type of lung cancer, with an annual mortality rate of ~400,000 worldwide (4). Chemotherapy and radiotherapy are the most common treatments for LSQCC; however, patient responses to these therapies are limited (5). Therefore, there is a requirement for additional agents to be developed that may enhance the response to these treatments.

Cyclooxygenase (COX)-2 serves an important role in the tumorigenesis of various types of cancer, and COX-2 inhibitors may effectively prevent tumor progression (6). Celecoxib is a selective COX-2 inhibitor; at the early stages of non-small-cell lung cancer (NSCLC), celecoxib was reported to increase the anti-cancer properties of preoperative chemotherapies, such as paclitaxel and carboplatin (7). In addition, celecoxib treatment upregulated the expression of death receptor 5 (DR5), decreased cell survival and induced apoptosis in NSCLCs (8).

Correspondence to: Mr. Chongzhi Gan, Department of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, 32 West Second Section, First Ring Road, Chengdu, Sichuan 610072, P.R. China
E-mail: ganchongzhi1018@hotmail.com

Abbreviations: ¹⁸F-FDG, 2-(¹⁸F)-fluoro-2-deoxy-d-glucose; *ATF4*, activating transcription factor 4; CC, correlation coefficient; CDDP, *cis*-diamminedichloroplatinum (II); CHOP, C/EBP homologous protein; COX, cyclooxygenase; DEG, differentially expressed gene; DR5, death receptor 5; ER, endoplasmic reticulum; FC, fold change; *FNI*, fibronectin 1; GO, gene ontology; lncRNA, long noncoding RNA; LSQCC, lung squamous cell carcinoma; mTOR, mammalian target of rapamycin; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; PPI, protein-protein interaction; RNA-seq, RNA-sequencing; *VEGFA*, vascular endothelial growth factor A

Key words: lung squamous cell carcinoma, celecoxib, long noncoding RNA, chemosensitivity, RNA sequencing, mammalian target of rapamycin signaling

Increased expression of COX-2 has been reported in LSQCC, and its inhibitor celecoxib is predicted as the beneficial target for chemotherapy (9). Although these previous studies have implied that celecoxib enhances the response sensitivity of chemotherapy in LSQCC, the specific molecular mechanisms of this inhibitor are still unknown. Several previous studies have indicated that celecoxib treatment may result in cell cycle arrest by downregulating the expression of p21 and p27, which may account for the reduction of cyclin-dependent kinase activity (10,11). In addition, celecoxib may contribute to the inhibition of angiogenesis by suppressing the expression of angiogenic factors in tumor cells (12). However, additional studies are required to comprehensively determine the mechanism of celecoxib on chemoprevention.

Long noncoding RNAs (lncRNAs) are a recently described RNA transcript species that is different from mRNAs and microRNAs. They are not transcriptional 'noise', but are important genes that function in numerous biological processes (13,14). Currently, several lncRNAs have been identified with significant functions in lung cancer; for example, the upregulation of *PVT1* was reported to promote oncogenesis in NSCLCs (15), and prostate cancer-associated transcript 6 was predicted as an oncogenic lncRNA in the growth and invasion of lung cancer cells (16). In addition, a recent study demonstrated that the novel lncRNA *onco-lncRNA 230* was able to induce invasion and apoptosis in LSQCC, and it was suggested as a possible new diagnostic marker for the disease (17). These imply that regulation of lncRNAs serves a key role in LSQCC. However, lncRNA expression under celecoxib treatment has not been reported. A previous study demonstrated that celecoxib treatment (50 μ M) induced significant overexpression of *Bcl-2*, *Bcl-extra large* and *survivin* following 24 h treatment, whereas no significant alterations in expression were identified in the activation of *caspase-3*, *caspase-8* or *caspase-9* (18). Another study revealed that the expression of *multidrug resistance-associated-4*, a member of the ATP-binding cassette transporters, was significantly upregulated in human LSQCC SK-MES-1 cells following treatment with 5 and 50 μ mol/l of celecoxib for 24, 48 and 72 h (19). These data suggested that celecoxib treatment may induce a series of variations in the metabolism of SK-MES-1 cells; however, no lncRNAs have been identified. Therefore, the present study used RNA-sequencing (RNA-seq), which facilitates transcript analysis in various cancers (20), to identify differentially expressed genes (DEGs) and differentially expressed lncRNAs (DE-LNRs) between SK-MES-1 cells cultured with or without celecoxib treatment. In addition, potential correlations were calculated, followed by pathway exploration of the lncRNAs. This study aimed to provide novel insight into celecoxib chemoprevention and to identify potential targeting markers for COX-2 induced LSQCC.

Materials and methods

Cell culture and drug treatment. The human LSQCC cell line SK-MES-1 was purchased from the Cell Bank of Type Culture Collection Chinese Academy of Sciences (Shanghai, China). Cells were cultured in the RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10%

Table I. Primer sequences of genes and lncRNA determined using reverse transcription-quantitative polymerase chain reaction.

Gene	Primer sequence (5'→3')
<i>VEGFA</i>	F: CTGTCTAATGCCCTGGAGCC R: ACGCGAGTCTGTGTTTTTGC
<i>FNI</i>	F: TTGTCCTGCACATGCTTTG R: CATGAAGCACTCAATTGGGCA
lnc-AP000769.1-2:10	F: GGGGAAGTAGTCTCGGGTAT R: GTCGTTATGAAGGCAATGTG
<i>GAPDH</i>	F: TGACAACCTTTGGTATCGTGGGAAGG R: AGGCAGGGATGATGTTCTGGAGAG

FNI, fibronectin 1; lnc, long noncoding; VEGFA, vascular endothelial growth factor A.

fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), at 37°C and 5% CO₂.

Cells at the logarithmic growth phase (at a confluency of 70-75%) were divided into two groups: i) Two identical SK-MES-1 cell samples were treated with 10 μ M celecoxib in 1% DMSO medium (celecoxib-treated group); and ii) two identical SK-MES-1 cell samples were treated with equal amounts of DMSO (Control group). Both groups were cultured for 48 h at 37°C.

RNA extraction and RNA-seq. A total of 5x10⁷ cells were utilized to isolate RNA using the RNeasy kit (catalog no. 74106; Qiagen Sciences, Inc., Gaithersburg, MD, USA) according to the manufacturer's protocol. RNA purity was analyzed with a NanoDrop 2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.), and the RNA was reverse transcribed into cDNA for library preparation using NEBNext Ultra RNA Library Prep kit for Illumina (catalog no. E7530L; New England BioLabs, Inc., Ipswich, MA, USA), following the manufacturer's protocol. Briefly, RNA (5 μ g) from each sample was sheared into small fragments (200 nucleotides) prior to cDNA synthesis using fragment buffer. Subsequently, the cDNA was blunt-ended and phosphorylated. A single 3' adenosine moiety and Illumina adapters were added on the repaired ends, followed by 15 cycles of polymerase chain reaction (PCR) according to the protocol of the kit. preamplification were performed using the NEB Phusion DNA polymerase (New England BioLabs, Inc.). RNA-seq was performed on the Illumina HiSeq 2000 Sequencing System (Illumina, Inc., San Diego, CA, USA) using the 2x50 paired-end sequencing method.

Pretreatment of RNA-seq data. Quality control (QC) of raw sequencing reads was performed using the next generation sequencing (NGS) QC Toolkit, as previously described (21). Briefly, the adaptor sequences in the reads were removed, and the low-quality reads with the base quality score <20 were filtered out. High quality sequences were defined having bases with a quality score >20 that accounted for >90% of its length. Subsequently,

Table II. Differentially expressed lncRNAs in the celecoxib-treated group and Control group.

A, Upregulated				
lncRNA	Value_1	Value_2	Log ₂ (FC)	q-value
lnc-C14orf166B-3:4	183.118	400.277	112.823	5.35x10 ⁻⁴
lnc-CNN3-3:1	112.248	179.237	0.675	5.06x10 ⁻⁸
lnc-CTSL1-2:2	327.718	549.936	0.747	2.63x10 ⁻²
lnc-CXCL3-1:1	128.057	34.035	141.023	8.89x10 ⁻¹³
lnc-ENTPD6-2:1	101.243	188.522	0.897	1.7x10 ⁻²
lnc-ERN1-1:1	750.668	164.504	113.187	8.84x10 ⁻⁸
lnc-HES1-10:1	258.042	694.213	142.777	5.96x10 ⁻⁴
lnc-HFE2-2:1	343.839	851.858	130.888	0
lnc-KIAA1257-3:1	132.568	21.211	0.678	6.09x10 ⁻⁴
lnc-KSR1-1:1	108.716	165.887	0.610	1.57x10 ⁻²
lnc-MOGAT2-5:1	930.449	140.722	0.597	2.81x10 ⁻²
lnc-MT2A-1:2	1990.13	3034.1	0.608	2.03x10 ⁻⁸
lnc-RAB44-3:1	517.827	879.917	0.765	1.22x10 ⁻⁸
lnc-RBM3-1:1	726.858	139.598	0.942	1.57x10 ⁻²
lnc-RP11-231C14.2.1-3:1	164.477	551.775	174.619	1.89x10 ⁻²
lnc-RSPH9-4:1	658.082	105.15	0.676	1.33x10 ⁻⁸
lnc-TRIB3-1:2	366.972	569.299	0.634	7.30x10 ⁻³
B, Downregulated				
lnc-AP000769.1-2:10	895.237	589.174	-0.604	6.98x10 ⁻⁵
lnc-BOLA3-2:2	136.839	0	-1.80x10 ⁻⁸	4.31x10 ⁻²
lnc-E2F2-1:1	200.807	118.647	-0.759	1.50x10 ⁻⁶
lnc-FOXG1-7:1	39.749	0	-1.80x10 ⁻⁸	4.16x10 ⁻¹³
lnc-GNLY-4:2	90.639	306.009	-156.656	3.67x10 ⁻³
lnc-KIAA0226-2:1	219.713	0.367	-258.257	1.62x10 ⁻⁴
lnc-LTBP3-2:5	11.504	730.114	-0.656	5.95x10 ⁻³
lnc-TOR1A-2:1	23.017	131.966	-0.803	1.40x10 ⁻²

FC, fold change; lncRNA, long noncoding RNA.




Figure 1. Scatter plot of FPKM in celecoxib-treated SK-MES-1 cells and untreated Control cells. Red dots represent upregulated genes in the celecoxib-treated group; green dots represent downregulated genes; and blue dots represent genes without differential expressions. The x-axis denotes cells in the Control group, and the y-axis denotes celecoxib-treated cells. FPKM, fragments per kilobase of exon per million fragments mapped.

the clean reads were aligned against the University of California Santa Cruz *Homo sapiens* reference genome (hg19 assembly, <http://www.genome.ucsc.edu/index.html>) using TopHat2 software (v2.0.9; <http://ccb.jhu.edu/software/tophat>) with the default parameters (22).

Identification of DEGs. Cufflinks (v2.2.1; <http://cufflinks.cbc.umd.edu/index.html>) software was used to calculate the fragments per kilobase of exon per million fragments mapped (FPKM), from which the gene expression values were obtained (23). The linear models for microarray analysis (limma; v3.10.3) package in R (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>) was used to select DEGs between the two groups (24), with the thresholds of $q\text{-value} < 0.05$ and $|\log_2(\text{FC})| > 0.58$; where FC is fold change.

Selection of DE-LNRs. LNCipedia 3.0 (<http://www.lncipedia.org>), an online storage of lncRNA annotation (25), was used

Table III. Top 10 identified KEGG enrichment pathways of identified DEGs.

A, Upregulated DEGs				
KEGG ID	Pathway name	Count ^a	Genes	P-value
970	Aminoacyl-tRNA biosynthesis	10	<i>AARS, CARS, EPRS, GARS, IARS</i>	4.49x10 ⁻⁷
4141	Protein processing in endoplasmic reticulum	15	<i>ATF4, DDIT3, DNAJB2, ERN1, HERPUD1</i>	1.05x10 ⁻⁶
260	Glycine, serine and threonine metabolism	6	<i>CBS, CTH, PHGDH, PSAT1, PSPH, SHMT2</i>	3.78x10 ⁻⁵
3060	Protein export	4	<i>HSPA5, SEC11C, SEC63, SRPRB</i>	1.09x10 ⁻³
520	Amino sugar and nucleotide sugar metabolism	5	<i>GFPT1, GFPT2, GMPPB, HKDC1, NAGK</i>	2.79x10 ⁻³
250	Alanine, aspartate and glutamate metabolism	4	<i>ASNS, GFPT1, GFPT2, GPT2</i>	3.84x10 ⁻³
4150	mTOR signaling pathway	5	<i>DDIT4, EIF4EBP1, RPS6KA2, ULK1, VEGFA</i>	3.97x10 ⁻³
860	Porphyrin and chlorophyll metabolism	4	<i>EPRS, FTH1, HMOX1, UROS</i>	1.11x10 ⁻²
5020	Prion diseases	3	<i>EGR1, HSPA5, IL1A</i>	3.39x10 ⁻²
450	Selenocompound metabolism	2	<i>CTH, MARS</i>	4.62x10 ⁻²
B, Downregulated DEGs				
KEGG ID	Pathway name	Count ^a	Genes	P-value
4350	TGF- β signaling pathway	4	<i>ID1, ID3, TGFβ2, THBS1</i>	1.94x10 ⁻⁴
5323	Rheumatoid arthritis	4	<i>CCL2, CSF1, CXCL6, TGFβ2</i>	2.65x10 ⁻⁴
5144	Malaria	3	<i>CCL2, TGFβ2, THBS1</i>	7.36x10 ⁻⁴
5200	Pathways in cancer	6	<i>AXIN2, E2F2, EGLN3, FN1, MITF, TGFβ2</i>	7.47x10 ⁻⁴
4512	ECM-receptor interaction	3	<i>COL1A1, FN1, THBS1</i>	3.23x10 ⁻³
5146	Amoebiasis	3	<i>COL1A1, FN1, TGFβ2</i>	6.01x10 ⁻³
5219	Bladder cancer	2	<i>E2F2, THBS1</i>	9.63x10 ⁻³
4380	Osteoclast differentiation	3	<i>CSF1, MITF, TGFβ2</i>	1.01x10 ⁻²
4060	Cytokine-cytokine receptor interaction	4	<i>CCL2, CSF1, CXCL6, TGFβ2</i>	1.32x10 ⁻²
4115	p53 signaling pathway	2	<i>RRM2, THBS1</i>	2.41x10 ⁻²

^aThe number of genes that were enriched in a specific pathway category. KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed gene.

to acquire information on lncRNAs. Subsequently, Cufflinks was used to screen the DE-LNRs. Similar to the selection of DEGs, the cut-off values were $q < 0.05$ and $|\log_2(\text{FC})| > 0.58$.

Enrichment analysis of the DEGs. To explore potential functions and pathways that the DEGs may participate in, function enrichment and pathway enrichment were implemented based on the Gene Ontology (GO; <http://www.geneontology.org>) (26) database and the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>) database, respectively, and the Database for Annotation, Visualization and Integration Discovery (DAVID; v6.8; <http://david.abcc.ncifcrf.gov>) (27). Selection criteria for a significant GO or KEGG pathway category were $P < 0.05$ with ≥ 2 genes enriched in a category.

Protein-protein interaction (PPI) network construction. The Search Tool for the Retrieval of Interacting Genes (STRING; v10.0, <http://string-db.org>) database was searched to discover potential interactions of proteins encoded by the identified DEGs (28). With the selection criterion of a combined score > 0.7 , a PPI network was established, which

was drawn using Cytoscape (v3.2.0; <http://cytoscape.org>) software (29).

Co-expression analysis of lncRNAs and mRNAs. For the identified DE-LNRs and DEGs, their correlation coefficient (CC) was calculated by Pearson correlation. The co-expressed DE-LNRs and DEGs were selected under the condition of $|CC| > 0.98$. Subsequently, enrichment analysis of the co-expressed DEGs was performed to predict biological functions of the DE-LNRs.

Validation of identified DEGs and lncRNA. To further confirm the identification of DEGs and DE-LNRs, expression levels of fibronectin 1 (*FN1*), vascular endothelial growth factor A (*VEGFA*) and lncAP000769.1-2:10 were determined using reverse transcription-quantitative PCR (RT-qPCR) in SK-MES-1 cells treated with 10 μM celecoxib or DMSO for 48 h. Total RNA was isolated from cells at a confluency of 70-75% using TRIzol agent (Takara Biotechnology Co., Ltd., Dalian, China), and reverse transcribed to cDNA using the PrimeScript RT Reagent kit (Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol. qPCR was




Figure 2. Protein-protein interaction network of the differentially expressed genes. Red circles represent upregulated genes, and green circles represent downregulated genes.




Figure 3. Enriched pathways of the co-expressed lncRNAs. Red indicates that the lncRNA was enriched in a specific pathway. Rows indicate pathways and columns indicate lncRNAs. lncRNA, long noncoding RNA.

performed using a SYBR Green kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) on a ViiA7 PCR instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermocycling conditions: 1 cycle of 50°C for 3 min and 95°C for 3 min; followed by 40 cycles of 95°C for 10 sec and 60°C for 30 sec. GAPDH was used as the internal control during expression analysis, and gene expression was calculated using the $2^{-\Delta\Delta C_q}$ method (30). Primer sequences are provided in Table I.

Statistical analysis. DEGs were screened using the limma package in R with the thresholds of $q < 0.05$ and $|\log_2(FC)| > 0.58$; DE-LNRs were screened using Cufflinks software with the same thresholds. Continuous variables are presented as the mean \pm standard deviation, and difference between groups was calculated using Student's t-test. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

DEGs and DE-LNRs identification. According to the aforementioned criteria, a set of 261 upregulated and 56 down-regulated DEGs were identified in celecoxib-treated group, compared with the untreated Control cells. Gene expressions in each group are presented in a scatter plot of FPKM (Fig. 1). Based on the predefined selection criterion, 17 lncRNAs were upregulated and 8 lncRNAs were downregulated in celecoxib-treated group compared with the untreated Control cells (Table II).

Pathway enrichment analysis of DEGs. KEGG pathway analysis indicated that the upregulated DEGs were significantly enriched in 12 pathway categories, including Aminoacyl-tRNA biosynthesis, protein processing in endoplasmic reticulum (ER), protein export, amino sugar and nucleotide sugar metabolism and mammalian target of rapamycin (mTOR) signaling pathway. The downregulated DEGs were enriched in 17 pathways, such as 'transforming growth factor (TGF)- β signaling pathway', 'extracellular matrix (ECM)-receptor interaction', 'cytokine-cytokine receptor interaction' and 'p53 signaling pathway' (Table III).

PPI network of DEGs. In the established PPI network (Fig. 2), several genes were highlighted that had high degrees; that is, a high number of connections between one gene and the others, such as VEGFA (degree=23), activating transcription factor (ATF)-4 (degree=19), FN1 (degree=16), urokinase-type plasminogen activator PLAU (degree=13), ATF3 (degree=11) and serpin E1 (SERPINE1; degree=10).

Co-expressed DE-LNRs and DEGs and their enriched functions. Using the criterion of $|CC| > 0.98$, the co-expressed DE-LNRs and DEGs were screened out. As presented in Table IV, *SERPINE1* was co-expressed with lnc-CTSL1-2:2 ($CC=0.998577$) and lnc-CXCL3-1:1 ($CC=0.986928$); *VEGFA* was linked with lnc-HES1-10:1 ($CC=0.98906$) and lnc-AP000769.1-2:10 ($CC=-0.99227$); lnc-HFE2-2:1 was co-expressed with *ATF4* ($CC=0.996159$) and *FN1* ($CC=-0.98714$); *ATF3* was co-expressed with lnc-KIAA1257-3:1 ($CC=0.990212$), lnc-KSR1-1:1 ($CC=0.99655$) and

Table IV. The most highly correlated co-expressed DE-LNRs and DEGs.

DE-LNR	DEG	CC
lnc-C14orf166B-3:4	VEGFA	0.999351
	CLDN11	-0.98538
lnc-CNN3-3:1	ACOT8	0.994477
	ATAD2	-0.99951
lnc-CTSL1-2:2	SERPINE1	0.998577
	AMER1	-0.99246
lnc-CXCL3-1:1	SERPINE1	0.986928
	AXIN2	-0.9893
lnc-ENTPD6-2:1	ACVR1	0.995922
	ASPN	-0.98602
lnc-ERN1-1:1	ABTB2	0.996183
	AXIN2	-0.98832
lnc-HES1-10:1	VEGFA	0.98906
	AMER1	-0.99383
lnc-HFE2-2:1	ATF4	0.996159
	FN1	-0.98714
lnc-KIAA1257-3:1	ATF3	0.990212
	LRFN1	-0.98734
lnc-KSR1-1:1	ATF3	0.99655
	CCDC80	-0.9997
lnc-MOGAT2-5:1	ACVR1	0.986953
	ASPN	-0.9935
lnc-MT2A-1:2	AASR	0.991019
	ATAD2	-0.99032
lnc-RAB44-3:1	ACOT8	0.997679
	ATAD2	-0.99846
lnc-RBM3-1:1	ACOT8	0.990015
	ATAD2	-0.99475
lnc-RP11-231C14.2.1-3:1	ATF3	0.993415
	CCDC80	-0.98512
lnc-RSPH9-4:1	ACOT8	0.990293
	CCNF	-0.988
lnc-TRIB3-1:2	ACOT8	
	ATAD2	-0.98366
lnc-AP000769.1-2:10	ASPN	0.987202
	VEGFA	-0.99227
lnc-BOLA3-2:2	CCNF	0.985247
	PLAU	-0.99288
lnc-E2F2-1:1	AMER1	0.987329
	AARS	-0.98601
lnc-FOXG1-7:1	AMER1	0.988729
	ANTXR2	-0.9897
lnc-GNLY-4:2	COL1A1	0.989359
	CDH13	-0.99856
lnc-KIAA0226-2:1	FN1	0.981655
	AARS	-0.99647
lnc-LTBP3-2:5	ASPN	0.993248
	BTG1	-0.993
lnc-TOR1A-2:1	ATOX1	0.98542
	CDH13	-0.99533

CC, correlation coefficient; DEG, differentially expressed gene; DE-LNR, differentially expressed long noncoding RNA.




Figure 4. Expression levels of (A) VEGFA, (B) FN and (C) lncAP000769 1-2:10 were determined in SK-MES-1 cells using reverse transcription-quantitative polymerase chain reaction. *P<0.05 vs. Control. FN1, fibronectin 1; lnc, long noncoding; VEGFA, vascular endothelial growth factor A.

lnc-RP11-231C14.2.1-3:1 (CC= 0.993415); lnc-BOLA3-2:2 was linked with *PLAU* (CC= -0.99288); and lnc-KIAA0226-2:1 was co-expressed with *FNI* (CC=0.981655).

According to the enrichment analysis results of the co-expressed DEGs, the co-expressed DE-LNRs were mainly enriched in the ‘p53 signaling pathway’ (for example, lnc-HES1-10:1, lnc-HFE2-2:1, lnc-KIAA1257-3:1 and lnc-KSR1-1:1; Fig. 3) and the ‘mTOR signaling pathway’ (for example, lnc-CTSL1-2:2, lnc-CXCL3-1:1, lnc-ERN1-1:1, lnc-HES1-10:1 and lnc-HFE2-2:1; Fig. 3).

Validations of DEGs and lncRNA. To verify the identification of possible DEGs and DE-LNRs, the expression levels of *VEGFA*, *FNI* and lnc-AP000769.1-2:10 were analyzed by RT-qPCR. The results revealed that the expression level of *VEGFA* was significantly increased in celecoxib-treated SK-MES-1 cells compared with untreated Control cells (Fig. 4A). However, the expression levels of *FNI* and lnc-AP000769.1-2:10 were significantly decreased in the celecoxib-treated group compared with the Control group (Fig. 4B and C, respectively). These results were consistent with the aforementioned bioinformatics analytical results.

Discussion

The present study identified a number of genes and lncRNAs that exhibited differential expression levels in celecoxib-treated human LSQCC SK-MES-1 cells, compared with untreated cells, including the genes *VEGFA*, *ATF4* and *FNI*, and the lncRNAs lnc-AP000769.1-2:10 and lnc-HFE2-2:1. Notably, many of the identified DEGs and DE-LNRs were significantly enriched in pathways like ‘protein processing in endoplasmic

reticulum’, ‘mTOR signaling pathway’ and ‘ECM-receptor interaction’.

VEGFA is an essential growth factor for stimulating angiogenesis, which often accompanies tumoral growth (31). A previous study reported that by upregulating the expression of FLJ10540, *VEGFA* activates the phosphatidylinositol 3-kinase/AKT signaling pathway, subsequently promoting cell invasion and migration in lung cancer (32). mTOR is located downstream of AKT signaling and functions in the control of angiogenesis and cell proliferation during tumor progression (33). *VEGFA* was also reported to activate the downstream mTOR signaling pathway to promote cancer growth (34). Notably, several therapeutic drugs for lung cancer have been reported to function through this pathway. 2-(¹⁸F)-fluoro-2-deoxy-d-glucose (¹⁸F-FDG) is a radiolabelled sugar molecule that is commonly used to monitor the therapeutic effects of chemotherapy for many malignant tumors, and the accumulation of ¹⁸F-FDG is regulated by the activation of mTOR signaling in NSCLC (35). *Cis*-diamminedichloroplatinum (II) (CDDP; also known as cisplatin) is an effective drug for the treatment of many cancers (36). However, resistance to this drug limited its potential use in lung cancer treatment. It was previously reported that overexpression of AKT activates the mTOR signaling pathway, which induces CDDP resistance in lung cancer cells (37). Therefore, inhibitors of the AKT/mTOR signaling pathway may provide a promising therapeutic target. In lung cancer, targeting of mTOR signaling was suggested as an effective method in developing therapeutic drugs (38). Curcumin, a natural extract of turmeric, is considered as an antitumoral agent, which was reported to enhance the anti-cancer ability of chemotherapy in

LSQCC by regulating multiple pathways such as VEGF signaling (39). Notably, *VEGFA* was also indicated to be enriched in the mTOR signaling pathway (36). In the present study, *VEGFA* was identified as an upregulated DEG in celecoxib-treated LSQCC cells, and was demonstrated to be significantly enriched in the mTOR signaling pathway. These data suggested that *VEGFA* may be a sensitive gene in response to celecoxib, and the increased expression may inhibit the activation of mTOR signaling, which may improve the anti-tumor effects of celecoxib on LSQCC cells.

In addition, lncRNAs may also serve crucial roles in the amplification of anti-tumor effects. Nuclear paraspeckle assembly transcript 1 (*Neat1*; ENST00000501122.2) is a factor required for the assembly of paraspeckle compartments in the cell (40). *Neat1*-containing paraspeckles were reported to be responsible for the regulation of chemosensitivity and may be induced by p53 (41). The biofunction of *Neat1* is similar to lnc-AP000769.1-2:3. However, no information about lnc-AP000769.1-2:10 has yet been reported. In the present study, lnc-AP000769.1-2:10 was closely correlated with *VEGFA*, which was enriched in the mTOR signaling pathway following celecoxib treatment. In addition, the expression of lnc-AP000769.1-2:10 was significantly decreased in celecoxib treated SK-MES-1 cells. Therefore, the present study hypothesized that this lncRNA may regulate *VEGFA* gene expression in the mTOR signaling pathway, which may facilitate to the enhancement of anti-tumor effect of celecoxib for LSQCC treatment.

ATF4 was reported to be associated with cisplatin sensitivity in lung cancer cell lines (42). Celecoxib has been demonstrated to induce the expression of DR5 (43). In addition, C/EBP homologous protein (CHOP) was revealed to serve a crucial role in celecoxib-induced DR5 expression and may also be upregulated by celecoxib (44). Inhibition of *ATF4* expression by small interfering RNAs was able to abolish CHOP induction, which indicated the involvement of *ATF4* in celecoxib-induced apoptosis (45). The ER is an essential site for protein processing. In many types cancer, the ER serves an important role in the structural maintenance of proteins in pivotal signaling pathways (46). Control of these proteins may offer promising target therapies. In the present study, *ATF4* was indicated as enriched in the protein processing in ER pathway, which suggested that it may influence the sensitivity of celecoxib in LSQCC through the regulation of protein processing.

The *FNI* protein may be involved in several cellular activities, such as cell adhesion and migration (47,48). In lung cancer, knockdown of *FNI* was previously reported to increase the chemosensitivity of cisplatin and promote apoptosis in tumor cells (49). Notably, in the present study, *FNI* expression was downregulated in the celecoxib-treated LSQCC cells, which suggested that the reduced expression of this gene may also enhance the sensitivity of tumor cells in response to celecoxib. In addition, *FNI* has been implicated in pathways such as the ECM-receptor interaction pathway in many types cancer (50,51). Consistent with these results, *FNI* was significantly enriched in the ECM-receptor interaction pathway in the present study, which indicated that *FNI* may exert its function through its involvement in this pathway. Results from the present study also predicted

that both *FNI* and *ATF4* were targets of lnc-HFE2-2:1, which suggested that the two genes may be regulated by this lncRNA in LSQCC cells following celecoxib treatment. However, there is still little information available about this lncRNA. Based on the present results, lnc-HFE2-2:1 may be a novel target to predict sensitivity of celecoxib for the treatment of LSQCC, through the regulation of *FNI* and *ATF4* expressions.

There were some limitations to the present study. First, although some genes and lncRNA had been validated in this study, the regulatory relationships between lncRNAs and DEGs have yet to be confirmed with *in vitro* experiments. Second, as LSQCC may develop from a number of lung cell dysfunctions, SK-MES-1 cells may not reflect the wider results of celecoxib. Therefore, different types of LSQCC cell lines should be used in future studies, and the intersection of DEGs and lncRNAs may be focused. Finally, an appropriate animal model should be used to confirm the identified DEGs and DE-LNRs, including investigations on the predicted signaling pathways.

In conclusion, genes (such as *VEGFA*, *ATF4* and *FNI*), and lncRNAs (such as lnc-AP000769.1-2:10 and lnc-HFE2-2:1) may be crucial molecules to enhance the anti-cancer effects of celecoxib treatment on LSQCC, and may be used as predictors for chemosensitivity of celecoxib. However, additional validation experiments are required in further studies.

References

1. Henley SJ, Richards TB, Underwood JM, Ehemann CR, Plescia M and McAfee TA; Centers for Disease Control and Prevention (CDC): Lung cancer incidence trends among men and women-United States, 2005-2009. *MMWR Morb Mortal Wkly Rep* 63: 1-5, 2014.
2. de Groot P and Munden RF: Lung cancer epidemiology, risk factors, and prevention. *Radiol Clin North Am* 50: 863-876, 2012.
3. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. *CA Cancer J Clin* 65: 5-298, 2015.
4. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 489: 519-525, 2012.
5. Bendale Y, Bendale V, Birari-Gawande P, Kadam A and Gund P: Tumor regression with ayurvedic rasayana therapy in squamous cell carcinoma of lungs. *Rasamruta* 7: 1-5, 2015.
6. Mascaux C, Martin B, Verdebout JM, Ninane V and Sculier JP: COX-2 expression during early lung squamous cell carcinoma oncogenesis. *Eur Respir J* 26: 198-203, 2005.
7. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW and Dannenberg AJ: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. *J Clin Oncol* 21: 2645-2650, 2003.
8. Liu X, Yue P, Zhou Z, Khuri FR and Sun SY: Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. *J Natl Cancer Inst* 96: 1769-1780, 2004.
9. Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ and Hong WK: The BATTLE to personalize lung cancer prevention through reverse migration. *Cancer Prev Res (Phila)* 4: 962-972, 2011.
10. Fu SL, Wu YL, Zhang YP, Qiao MM and Chen Y: Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. *World J Gastroenterol* 10: 1971-1974, 2004.
11. Mineo TC, Ambrogi V, Cufari ME and Pompeo E: May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma? *Eur J Cardiothorac Surg* 38: 245-252, 2010.

12. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB and Bisen PS: Biology of Cox-2: An application in cancer therapeutics. *Curr Drug Targets* 12: 1082-1093, 2011.
13. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. *Cell* 136: 629-641, 2009.
14. Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. *Mol Cell* 43: 904-914, 2011.
15. Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS and Feng XJ: Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. *Int J Clin Exp Pathol* 7: 6929-6935, 2014.
16. Wan L, Zhang L, Fan K, Cheng ZX, Sun QC and Wang JJ: Knockdown of long noncoding RNA PCAT6 inhibits proliferation and invasion in lung cancer cells. *Oncol Res* 24: 161-170, 2016.
17. Tang CY, Silva-Fisher JM, Dang HX, White NM and Maher CA: Abstract 971: A novel long noncoding RNA, onco-lncRNA 230, induces apoptosis and invasion in lung squamous cell carcinoma. *Cancer Res* 76 (14 Suppl): S971, 2016.
18. Gradilone A, Silvestri I, Scarpa S, Morrone S, Gandini O, Pulcinelli FM, Gianni W, Frati L, Aglianò AM and Gazzaniga P: Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. *Oncol Rep* 17: 823-828, 2007.
19. Gradilone A, Pulcinelli FM, Lotti LV, Martino S, Mattiello T, Frati L, Aglianò AM and Gazzaniga P: Celecoxib induces MRP-4 in lung cancer cells: Therapeutic implications. *J Clin Oncol* 25: 4318-4320, 2007.
20. Lin L, Abo R, Dolcen D, Paquette R, Laing A, de Waal L, Thorner A, Ducar M, Ziaugra L, Wollison B, *et al*: Abstract 1115: Targeted RNA sequencing improves transcript analysis in cancer samples. *Cancer Res* 75 (15 Suppl): S1115, 2015.
21. Patel RK and Jain M: NGS QC Toolkit: A toolkit for quality control of next generation sequencing data. *PLoS One* 7: e30619, 2012.
22. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL: TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36, 2013.
23. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7: 562-578, 2012.
24. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43: e47, 2015.
25. Volders PJ, Verheggen K, Menschaert G, Vandepoele K, Martens L, Vandesompele J and Mestdagh P: An update on LNCipedia: A database for annotated human lncRNA sequences. *Nucleic Acids Res* 43 (Database Issue): D174-D180, 2015.
26. Gene Ontology Consortium: Gene ontology consortium: Going forward. *Nucleic Acids Res* 43 (Database Issue): D1049-D1056, 2015.
27. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation, visualization and Integrated discovery. *Genome Biol* 4: P3, 2003.
28. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguéz P, Doerks T, Stark M, Muller J, Bork P, *et al*: The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 39 (Database Issue): D561-DD68, 2011.
29. Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. *Bioinformatics* 27: 431-432, 2011.
30. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using rea-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
31. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. *J Intern Med* 273: 114-127, 2013.
32. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, *et al*: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. *PLoS One* 4: e5052, 2009.
33. Inoki K, Corradetti MN and Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 37: 19-24, 2005.
34. Chen B, Zhang C, Dong P, Guo Y and Mu N: Molecular regulation of cervical cancer growth and invasion by VEGFa. *Tumor Biol* 35: 11587-11593, 2014.
35. Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T and Yamamoto N: Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. *Lung Cancer* 83: 197-204, 2014.
36. Petryk AA, Giustini AJ, Gottesman RE, Kaufman PA and Hoopes PJ: Magnetic nanoparticle hyperthermia enancement of cisplatin chemotherapy cancer treatment. *Int J Hyperthermia* 29: 845-851, 2013.
37. Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. *Cancer Res* 67: 6325-6332, 2007.
38. Ekman S, Wynes MW and Hirsch FR: The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. *J Thorac Oncol* 7: 947-953, 2012.
39. Zhao W, Wang Y, Wang Y, Gao N, Han Z and Yu H: Potential anti-cancer effect of curcumin in human lung squamous cell carcinoma. *Thoracic Cancer* 6: 508-516, 2015.
40. Imamura K, Imamachi N, Akizuki G, Kumakura M, Kawaguchi A, Nagata K, Kato A, Kawaguchi Y, Sato H, Yoneda M, *et al*: Long noncoding RNA NEAT1-dependent SFPQ relocation from promotor region to paraspeckle mediates IL8 expression upon immune stimuli. *Mol Cell* 53: 393-406, 2014.
41. Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, Boeckx B, Wijnhoven PW, Radaelli E, Vermi W, *et al*: p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. *Nat Med* 22: 861-868, 2016.
42. Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K and Kohno K: Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. *Cancer Res* 63: 8592-8595, 2003.
43. He Q, Luo X, Jin W, Huang Y, Reddy MV, Reddy EP and Sheikh MS: Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP. *Oncogene* 27: 2656-2660, 2008.
44. Kim SJ, Ha GH, Bae JH, Kim GR, Son CH, Park YS, Yang K, Oh SO, Kim SH and Kang CD: COX-2 and endoplasmic reticulum stree-independent induction of ULBP-1 and enhancement of sensitivity to NK cell-mediated cytotoxicity by celecoxib in colon cancer cells. *Exp Cell Res* 330: 451-459, 2015.
45. Oh YT, Liu X, Yue P, Kang S, Chen J, Taunton J, Khuri FR and Sun SY: ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1. *J Biol Chem* 285: 41310-41319, 2010.
46. Dong HS, Kim MK, Kim HS, Chung HH and Yong SS: Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. *Ann N Y Acad Sci* 1271: 20-32, 2012.
47. Veluscek G, Li Y, Yang SH and Sharrocks AD: Jun-mediated changes in cell adhesion contribute to mouse embryonic stem cell exit from ground state pluripotency. *Stem Cells* 34: 1213-1224, 2016.
48. Lou X, Xu H, Jin C, Tian W, Yu W, Dong D, Cheng L, Huang B, Jiang H and Lin B: SOX2 targets fibronectin 1 to promote cell migration and invasion in ovarian cancer: New molecular leads for therapeutic intervention. *OMICS* 17: 520-508, 2013.
49. Gao W, Liu Y, Qin R, Liu D and Feng Q: Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line. *Biochem Biophys Res Commun* 476: 35-41, 2016.
50. Fang L, Gao X, Jing W, Chao G, Li X, Li X, Gong X and Zeng X: Transcriptome sequencing to identify transcription factor regulatory network and alternative splicing in endothelial cells under VEGF stimulation. *J Mol Neurosci* 58: 170-177, 2016.
51. Wang Y and Li Y: Analysis of molecular pathways in pancreatic ductal adenocarcinomas with a bioinformatics approach. *Asian Pac J Cancer Prev* 16: 2561-2567, 2015.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.